Carnosic acid suppresses the production of amyloid-β 1-42 and 1-43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells

Neuroscience Research

Volumn 79, Issue 1, 2014, Pages 83-93

  Yoshida, Hidemi ^a   Meng, Pengfei ^a   Matsumiya, Tomoh ^a   Tanji, Kunikazu ^a   Hayakari, Ryo ^a   Xing, Fei ^a   Wang, Liang ^a   Tsuruga, Kazushi ^a   Tanaka, Hiroshi ^a,b   Mimura, Junsei ^a   Kosaka, Kunio ^c   Itoh, Ken ^a   Takahashi, Ippei ^b   Imaizumi, Tadaatsu ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Osaka City University Medical School   (Japan)

Author keywords

A ; ADAM17; Alzheimer's disease; Astrocytes; Carnosic acid; TACE

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-43]; BETA SECRETASE 1; CARNOSIC ACID; RESVERATROL; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA CELL; CONTROLLED STUDY; DRUG EFFECT; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REOXYGENATION; ALZHEIMER DISEASE; ASTROCYTE; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; NEUROBLASTOMA CELL;

ADAM17; ALZHEIMER'S DISEASE; ASTROCYTES; AΒ; CARNOSIC ACID; TACE;

ADAM PROTEINS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASTROCYTOMA; CELL LINE, TUMOR; DITERPENES, ABIETANE; HUMANS; PEPTIDE FRAGMENTS; PLANT EXTRACTS;

EID: 84896723048     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2013.11.004     Document Type: Article

References (59)

1. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. Amyloid β-protein (Aβ) assembly: Aβ 40 and Aβ 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U. S. A. 2002, 100:330-335.
2. Bushong E.A., Martone M.E., Jones Y.Z., Ellisman M.H. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J. Neurosci. 2002, 22:183-192.
3. Buxbaum J.D., Liu K.-N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., Black R.A. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 1998, 273:27765-27767.
4. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 2009, 35:128-140.
5. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell 2010, 142:320-332.
6. Fahrenholz F. Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 2007, 4:412-417.
7. Farfara D., Lifshitz V., Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J. Cell Mol. Med. 2008, 12:762-780.
8. Furukawa K., Sopher B.L., Rydel R.E., Begley J.G., Pham D.G., Martin G.M., Fox M., Mattson M.P. Increased activity-regulating and neuroprotective efficacy of α-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 1996, 67:1882-1896.
9. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest. 2005, 115:1121-1129.
10. Hampel H., Bürger K., Teipel S.J., Bokde A.L., Zetterberg H., Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's Dement. 2008, 4:38-48.
11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
12. Herskovits A.Z., Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 2013, 23:746-758.
13. Hirayama A., Horikoshi Y., Maeda M., Ito M., Takashima S. Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome. Brain Dev. 2003, 25:180-185.
14. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
15. Imaizumi T., Murakami K., Ohta K., Seki H., Matsumiya T., Meng P., Hayakari R., Xing F., Aizawa-Yashiro T., Tatsuta T., Yoshida H., Kijima H. MDA5 and ISG56 mediate CXCL10 expression induced by Toll-like receptor 4 activation in U373MG human astrocytoma cells. Neurosci. Res. 2013, 76:195-206.
16. Ishikawa A., Yoshida H., Metoki N., Toki T., Imaizumi T., Matsumiya T., Yamashita K., Taima K., Satoh K. Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. Neurosci. Res. 2007, 59:406-412.
17. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 2001, 292:1550-1552.
18. Johnson J.A., Johnson D.A., Kraft A.D., Calkins M.J., Jakel R.J., Vargas M.R., Chen PC. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann. N.Y. Acad. Sci. 2008, 1147:61-69.
19. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebocontrolled, crossover investigation. Am. J. Clin. Nutr. 2010, 91:1590-1597.
20. Kirkitadze M.D., Kowalska A. Molecular mechanisms initiating amyloid β-fibril formation in Alzheimer's disease. Acta Biochim. Pol. 2005, 52:417-423.
21. Kojro E., Fahrenholz F. The non-amyloidogenic pathway: structure and function of α-secretases. Subcell. Biochem. 2005, 38:105-127.
22. Kosaka K., Mimura J., Itoh K., Satoh T., Shimojo Y., Kitajima C., Maruyama A., Yamamoto M., Shirasawa T. Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells. J. Biochem. 2010, 147:73-81.
23. Kuhn P.-H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Roßner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive (-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
24. Li L., Zhang X., Yang D., Luo G., Chen S., Le W. Hypoxia increases Abeta generation by altering β- and γ-cleavage of APP. Neurobiol. Aging 2009, 30:1091-1098.
25. Li Q.Y., Wang H.M., Wang Z.Q., Ma J.F., Ding J.Q., Chen S.D. Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. Neurosci. Lett. 2010, 481:154-158.
26. Li C., Zhao R., Gao K., Wei Z., Yin M.Y., Lau L.T., Chui D., Hoi Yu A.C. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:67-80.
27. Marshall A.J., Rattray M., Vaughan P.F.T. Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative α-secretases, ADAM10 and TACE, without altering their mRNA levels. Brain Res. 2006, 1099:18-24.
28. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
29. Meng P., Yoshida H., Matsumiya T., Imaizumi T., Tanji K., Xing F., Hayakari R., Dempoya J., Tatsuta T., Aizawa-Yashiro T., Mimura J., Kosaka K., Itoh K., Satoh K. Carnosic acid suppresses the production of amyloid-β 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. Neurosci. Res. 2013, 75:94-102.
30. Meziane H., Dodart J.-C., Mathis C., Little S., Clements J., Paul S.M., Ungerer A. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12683-12688.
31. Mimura J., Kosaka K., Maruyama A., Satoh T., Harada N., Yoshida H., Satoh K., Yamamoto M., Itoh K. Nrf2 regulates NGF mRNA induction by carnosic acid in T98G glioblastoma cells and normal human astrocytes. J. Biochem. 2011, 50:209-217.
32. Nord C.N., Sundqvist J., Anderson E., Fried G. Analysis of oestrogen regulation of α-, β-, and γ-secretase gene and protein expression in cultured human neuronal and glial cells. Neurodegener. Dis. 2010, 7:349-364.
33. Park J.A., Kim S., Lee S.Y., Kim C.S., Kim do.K., Kim S.J., Chun H.S. Beneficial effects of carnosic acid on dieldrin-induced dopaminergic neuronal cell death. Neuroreport 2008, 19:1301-1304.
34. Peers C., Dallas M.L., Boycott H.E., Scragg J.L., Pearson H.A., Boyle J.P. Hypoxia and neurodegeneration. Ann. N. Y. Acad. Sci. 2009, 1177:169-177.
35. Preyat N., Leo O. Sirtuin deacylases: a molecular link between metabolism and immunity. J. Leukoc. Biol. 2013, 93:669-680.
36. Rahman S., Islam R. Mammalian SIRT1: insights on its biological functions. Cell Commun. Signal. 2011, 9:11.
37. Saito T., Suemoto T., Brouwers N., Sleegers K., Funamoto S., Mihira N., Matsuba Y., Yamada K., Nilsson P., Takano J., Nishimura M., Iwata N., Van Broeckhoven C., Ihara Y., Saido T.C. Potent amyloidogenicity and pathogenicity of Aβ43. Nat. Neurosci. 2011, 14:1023-1032.
38. Sandebring A., Welander H., Winblad B., Graff C., Tjernberg L.O. The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease. PLoS One 2013, 8:e55847. Erratum in: PLoS One 8. 10.1371/annotation/b4d7aee1-6578-4e73-b15d-67aef9b3da8c.
39. Satoh T., Izumi M., Inukai Y., Tsutsum Y., Nakayama N., Kosaka K., Shimojo Y., Kitajima C., Itoh K., Yokoi T., Shirasawa T. Carnosic acid protects neuronal HT22 cells through activation of the antioxidant-responsive element in free carboxylic acid- and catechol hydroxyl moieties-dependent manners. Neurosci. Lett. 2008, 434:260-265.
40. Satoh T., Kosaka K., Itoh K., Kobayashi A., Yamamoto M., Shimojo Y., Kitajima C., Cui J., Kamins J., Okamoto S.-I., Izumi M., Shirasawa T., Lipton S.A. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J. Neurochem. 2008, 104:1116-1131.
41. Satoh A., Brace C.S., Ben-Josef G., West T., Wozniak D.F., Holtzman D.M., Herzog E.D., Imai S. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J. Neurosci. 2010, 30:10220-10232.
42. Seip W.F., Evans G.L. Atmospheric analysis and redox potentials of cultured media in the GasPak system. J. Clin. Microbiol. 1980, 11:226-233.
43. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
44. Seubert P., Oltersdorf T., Lee M.G., Barbour R., Blomquist C., Davis D.L., Bryant K., Fritz L.C., Galasko D., Thal L.J., Lieberburg I., Schenk D.B. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloidpeptide. Nature 1993, 361:260-263.
45. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Hirai S. Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998, 158:134-140.
46. SW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J. Neurosci. 2004, 24:7707-7717.
47. Takahashi T., Tabuchi T., Tamaki Y., Kosaka K., Takikawa Y., Satoh T. Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism. Biochem. Biophys. Res. Commun. 2009, 382:549-554.
48. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
49. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
50. Wang S., Wang R., Chen L., Bennett D.A., Dickson W., Wang D.S. Expression and functional profiling of neprilysin, insulin degrading enzyme and endothelin converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem. 2010, 115:47-57.
51. Welander H., Frånberg J., Graff C., Sundström E., Winblad B., Tjernberg L.O. Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains. J. Neurochem. 2009, 110:697-706.
52. Xu D., Sharma C., Hemler M. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J. 2009, 23:3674-3681.
53. Yasojima K., McGeer E.G., McGeer P.L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001, 919:115-121.
54. Yoshida H., Imaizumi T., Tanji K., Matsumiya T., Sakaki H., Kimura D., Cui X.-F., Kumagai M., Tamo W., Shibata T., Hatakeyama M., Sato Y., Satoh K. Platelet-activating factor enhances the expression of vascular endothelial growth factor in normal human astrocytes. Brain Res. 2002, 944:65-72.
55. Yoshida H., Imaizumi T., Tanji K., Sakaki H., Metoki N., Hatakeyama M., Yamashita K., Ishikawa A., Taima K., Sato Y., Kimura H., Satoh K. Platelet-activating factor enhances the expression of nerve growth factor in normal human astrocytes under hypoxia. Mol. Brain Res. 2005, 133:95-101.
56. Yoshida H., Metoki N., Ishikawa A., Imaizumi T., Matsumiya T., Tanji K., Ota K., Ohyama C., Satoh K. Edaravone improves the expression of nerve growth factor in human astrocytes subjected to hypoxia/reoxygenation. Neurosci. Res. 2010, 66:284-289.
57. Yoshida H., Mimura J., Imaizumi T., Matsumiya T., Ishikawa A., Metoki N., Tanji K., Ota K., Hayakari R., Kosaka K., Itoh K., Satoh K. Edaravone and carnosic acid synergistically enhance the expression of nerve growth factor in human astrocytes under hypoxia/reoxygenation. Neurosci. Res. 2011, 69:291-298.
58. Zhang X., Le W. Pathological role of hypoxia in Alzheimer's disease. Exp. Neurol. 2010, 223:299-303.
59. Zhang F., Liu J., Shi J.S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 2010, 636:1-7.